article thumbnail

One way to reduce medical errors? Connect doctors with other doctors

SCIENMAG: Medicine & Health

We trust our doctors with our lives, but the sad and scary fact is that doctors can get things wrong. Approximately 100,000 Americans die each year due to medical errors and recent studies have found that 10 to 15% of all clinical decisions regarding patient diagnosis and treatment are wrong.

Doctors 84
article thumbnail

After surprise trial failure, ALS doctors brace for one less treatment option

BioPharma Drive: Drug Pricing

Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.

Doctors 125
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Immuno-oncology innovations redefining cancer treatment in 2024

Drug Target Review

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.

Treatment 122
article thumbnail

AI Uses Zero-Shot Learning to Find Existing Drugs for Treating Rare Diseases

Nvidia Developer: Drug Discovery

A groundbreaking drug-repurposing AI model could bring new hope to doctors and patients trying to treat diseases with limited or no existing treatment options. A groundbreaking drug-repurposing AI model could bring new hope to doctors and patients trying to treat diseases with limited or no existing treatment options.

Disease 143
article thumbnail

As ALS research booms, one treatment center finds itself in the spotlight

BioPharma Drive: Drug Pricing

The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.

Research 142
article thumbnail

The future of lymphoma treatment

Drug Target Review

ARC-02 is our anti-CD79b targeting ADC in development for the treatment of relapsed/refractory (r/r) follicular lymphoma (FL), for which there are currently no approved ADCs, as well as r/r diffuse B-cell lymphoma (DLBCL). The ADC uses the same antibody and drug payload as the approved Polivy®, however, it uses Araris’ linker technology.

Treatment 114
article thumbnail

Healx teams up with Mission: Cure to discover and advance the world’s first treatments for chronic pancreatitis

Drug Discovery Today

Mission: Cure is a coalition of patients, doctors, researchers and entrepreneurs who are committed to advancing new therapies and cures for currently untreatable diseases. Their primary disease focus is on chronic pancreatitis, a rare inflammatory condition that affects over a million people across the globe.

Treatment 113